After demonstrating the key role of the lncRNA-PI3K axis in regulating TKI resistance, we explored the therapeutic potential of the PI3K inhibitor alpelisib in treating patients with resistant CML. This evidence concerns the gene PIK3CG and chronic myelogenous leukemia, BCR-ABL1 positive.